Skip to main content

Military Health System

Influenza Surveillance Trends and Influenza Vaccine Effectiveness Among Department of Defense Beneficiaries During the 2019–2020 Influenza Season

Image of Captured in 2011, this transmission electron microscopic (TEM) image depicts some of the ultrastructural details displayed by H3N2 influenza virions, responsible for causing illness in Indiana and Pennsylvania in 2011. See PHIL 13469, for the diagrammatic representation of how this Swine Flu stain came to be, through the “reassortment” of two different Influenza viruses.  Credit: CDC/ Dr. Michael Shaw; Doug Jordan, M.A. Captured in 2011, this transmission electron microscopic (TEM) image depicts some of the ultrastructural details displayed by H3N2 influenza virions, responsible for causing illness in Indiana and Pennsylvania in 2011. See PHIL 13469, for the diagrammatic representation of how this Swine Flu stain came to be, through the “reassortment” of two different Influenza viruses.
Credit: CDC/ Dr. Michael Shaw; Doug Jordan, M.A.

Recommended Content:

Medical Surveillance Monthly Report

What are the New Findings?

Influenza B was the predominant influenza type starting from the beginning of Nov. 2019. Influenza A(H1N1)pdm09 occurred actively 3 weeks thereafter, and then co-circulated highly with influenza B through the end of March 2020. The estimated VE (46%) indicated that the influenza vaccine during the 2019–2020 influenza season was moderately effective against these influenza viruses.

What is the Impact on Readiness and Force Health Protection?

Influenza surveillance conducted by DODGRS during the 2019–2020 influenza season identified circulating influenza virus (sub)types, provided timely data on the genetic characteristics of the circulating viruses, and estimated influenza VE. These surveillance data and findings help military authorities prioritize health resources and better plan appropriate health intervention measures for DOD service members and their beneficiaries.

Abstract

Laboratory-based influenza surveillance was conducted in the 2019–2020 influenza season among Department of Defense (DOD) beneficiaries through the DOD Global Respiratory Pathogen Surveillance Program (DODGRS). Sentinel and participating sites submitted 28,176 specimens for clinical diagnostic testing. A total of 5,529 influenza-positive cases were identified. Starting at surveillance week 45 (3–9 Nov. 2019), influenza B was the predominant influenza type, followed by high activity of influenza A(H1N1)pdm09 three weeks thereafter. Both influenza B and influenza A(H1N1)pdm09 were then highly co-circulated through surveillance week 13 (22–28 March 2020). End-of-season influenza vaccine effectiveness (VE) was estimated using a test-negative case-control study design. The adjusted end-of-season VE for all beneficiaries, regardless of influenza type or subtype, was 46% (95% confidence interval: 40%–52%). The influenza vaccine was moderately effective against influenza viruses during the 2019–2020 influenza season.

Background

Influenza viruses change from year to year as they undergo constant antigenic drifts and potential antigenic shifts. Because of the changing nature of these viruses, it is crucial to conduct annual surveillance to determine the circulating viruses and to detect changes in the viruses during the influenza season. Seasonal influenza vaccination is considered the main strategy to protect against influenza viruses, combat influenza infection, and reduce disease severity. To improve vaccine effectiveness (VE) against influenza viruses, the strains used in the influenza vaccine need to be updated regularly based on the surveillance findings. Every year, the Department of Defense (DOD) Global Respiratory Pathogen Surveillance Program (DODGRS) performs routine respiratory pathogen surveillance among DOD service members and their beneficiaries, and evaluates influenza VE. The objective of this report is to describe influenza surveillance trends and the end-of season VE estimates among DOD beneficiaries during the 2019–2020 influenza season.

Methods

Surveillance population

The participant selection criteria in DODGRS have been described elsewhere.1,2 Briefly, all participants were selected at sentinel or participating sites throughout the U.S. and around the world, using criteria which meet the influenza-like illness (ILI) case definition. An ILI case is defined as a patient who exhibits a fever greater than or equal to 100.5 °F and a cough or sore throat that presents within 72 hours after illness onset, or has physician-determined ILI. Respiratory specimens were collected by nasopharyngeal wash or nasopharyngeal swab. Each sentinel or participating site was requested to submit 6–10 respiratory specimens per week for laboratory testing. Patients who had received at least 1 influenza vaccine dose 14 days or more before an ILI encounter were considered vaccinated. Vaccination status was verified through the records from the DOD Electronic Immunization Tracking System or self-reported questionnaire for each outpatient.

Laboratory testing

Influenza testing was conducted in 1 of 3 laboratories located within Landstuhl Regional Medical Center, Brooke Army Medical Center, or the U.S. Air Force School of Aerospace Medicine (USAFSAM). The specimens collected from the sentinel and participating sites were processed and subjected to testing via a multiplex respiratory pathogen panel, reverse transcriptase polymerase chain reaction (RT-PCR), and/or viral culture. In this way, the influenza-positive cases and other respiratory pathogens were identified and confirmed. The laboratory-confirmed influenza viruses were further genetically characterized via Illumina next-generation sequencing (NGS) technology and analyzed using the Iterative Refinement Meta-Assembler (IRMA) package,3 BioEdit software,4 and components of the DNASTAR Lasergene Core Suite.5

A test-negative case-control study design was used to estimate influenza VE. The VE analysis was limited to surveillance weeks 46–12 (10 November 2019 to 21 March 2020), when approximately 10% or greater influenza positivity rate occurred, with an aim to minimize any potential bias due to high ratio of controls to cases that would typically occur earlier or later in the influenza season. Service members, due to their usually high influenza vaccination rate (>90%), and outpatients less than 6 months of age were excluded from the VE analysis. Age was categorized into 3 groups (i.e., children: 6 months to 17 years; adults: 18–64 years; and the elderly: 65 years or older). The odds of influenza vaccination among beneficiaries with laboratory-confirmed influenza-positive status (cases) were compared to the odds of influenza vaccination among beneficiaries who tested influenza negative (controls), using backward stepwise multiple logistic regression models in SAS /STAT software, version 9.4 (2014, SAS Institute, Cary, NC). End-of-season VE was calculated as (1 – adjusted odds ratio) × 100% and estimates were presented with their associated 95% confidence intervals (CIs). VE estimates were adjusted for potential confounding factors, such as age group, sex, specimen collection date, and geographical region (i.e., eastern U.S., western U.S., and outside the continental U.S.). A point estimate of VE was considered statistically significant if the 95% CI did not contain zero or a negative value. In addition to VE estimated for all influenza in the entire beneficiary population, VE was estimated against any specific influenza, by influenza virus (sub)types in separate models [i.e., influenza A, A(H1N1)pdm09, A(H3N2), or influenza B], and in stratified models by beneficiary age group (i.e., children, adults, or the elderly).

Results

Influenza virus and other pathogen surveillance

During the 2019–2020 influenza season, a total of 28,176 specimens were collected from 4 commands including 114 geographical locations (Table 1, data not shown). These specimens included 23,466 (83.3%) from U.S. Northern Command, 2,989 (10.6%) from U.S. European Command, 1,699 (6.0%) from U.S. Indo-Pacific Command, and 22 (0.1%) from U.S. Central Command (data not shown). Of those collected, 15,763 (55.9%) specimens were from male outpatients and 12,413 (44.1%) were from female outpatients (data not shown). There were 13,353 (47.4%) specimens collected from service members, 7,091 (25.2%) from children, and 7,732 (27.4%) from other non-service member beneficiaries including retirees and spouses, etc. (18 years or older) (data not shown).

The distribution of influenza (sub)types/lineages identified during the influenza season is shown in Table 1. Of the specimens tested, 5,529 (19.6%) were confirmed influenza positive. Among the 3,098 influenza A-positive specimens that were subtyped, 2,885 (93.1%) were influenza A(H1N1)pdm09, and 213 (6.9%) were influenza A(H3N2). A total of 2,336 specimens were characterized as influenza B positive. Of the influenza B with lineage information available, 856 (99.3%) belonged to the B/Victoria lineage, and 6 (0.7%) belonged to B/ Yamagata lineage. Moreover, 31 specimens tested positive for dual influenza infections. Among the 7,681 (27.3%) noninfluenza pathogens, 6,865 (89.4%) specimens were found to be positive for single noninfluenza respiratory pathogens, and 816 (10.6%) for noninfluenza pathogen coinfections (Table 1).

The numbers and percentages of influenza (sub)types that tested positive by week are presented in Figures 1a and 1b. Also, data from the 2018–2019 influenza season are provided to indicate seasonal influenza change from year to year. The influenza seasonal pattern generally revealed the influenza activity in the area of Northern Command from which the vast majority of specimens were collected. During the beginning of the influenza season (surveillance weeks 40–44; 29 Sept. to 2 Nov. 2019), low levels of influenza activity occurred, with small positivity rates of influenza A(H1N1) pdm09, influenza A(H3N2), and influenza B viruses (<3.0%; Figure 1b). However, starting from surveillance week 45 (3–9 Nov. 2019), influenza B was predominant. Three weeks thereafter, influenza A(H1N1)pdm09 activity increased quickly. From surveillance weeks 50 through 11 (8 Dec. 2019 to 14 March 2020), the activities of both influenza B and influenza A(H1N1)pdm09 remained highly elevated. The highest numbers of specimens that tested positive for both influenza B and A(H1N1)pdm09 occurred in surveillance week 7 (9–15 February 2020; Figure 1a). The results indicated peak influenza activity for the influenza season occurred from the end of Dec. 2019 through the end of Feb. 2020.

Genetic characteristics of influenza virus

From 30 Sept. 2019 through 14 Aug. 2020, 2,652 influenza sequences were either generated at USAFSAM or contributed by partner laboratories at the Armed Forces Research Institute of Medical Sciences (AFRIMS), the Naval Medical Research Unit No. 2 (NAMRU-2), the Naval Health Research Center (NHRC), or the U.S. Army Medical Research Directorate-Kenya (USAMRD-K). In total, 1,157 (43.6%) influenza A(H1N1)pdm09, 255 (9.6%) influenza A(H3N2), 1,229 (46.3%) influenza B/Victori lineage (Figures 2a-2c), and 11 (0.4%) influenza B/Yamagata lineage hemagglutinin (HA) sequences were analyzed (data not shown).

All 1,157 of the influenza A(H1N1) pdm09 HA sequences were in clade 6B.1A (Figure 2a) and contained the substitution S183P relative to the vaccine strain, with 82.8% in subgroup 183P-5A, 12.0% in 183P-5B, and 5.2% in 183P-7 (data not shown). The average HA protein similarity of A(H1N1) pdm09 for the influenza season was 98.0% ± 0.38% (mean ± SD) compared with the 2019–2020 influenza vaccine A(H1N1)pdm09 component, A/Brisbane/02/2018-like virus (clade 6B.1A) (data not shown). Among the 255 influenza A(H3N2) HA sequences, 91.8% were in clade 3C.2a1b and 8.2% were in clade 3C.3a (Figure 2b). The average HA protein similarity of A(H3N2) for the influenza season was 96.5% ± 0.91% compared with the 2019–2020 influenza vaccine A(H3N2) component, A/Kansas/14/2017-like virus (clade 3C.3a) (data not shown). Among the 1,229 influenza B/Victoria HA sequences, 96.5% were in clade V1A.3 containing a three amino acid deletion at positions 162–164 and 3.5% were in clade V1A.1 containing a two amino acid deletion at positions 162–163 (Figure 2c). The average HA protein similarity of B/Victoria for the influenza season was 98.3% ± 0.24% compared with the 2019–2020 influenza vaccine B/Victoria component, B/Colorado/06/2017-like virus (clade V1A.1) (data not shown). All 11 of the influenza B/Yamagata HA sequences were in clade Y3 and had an average protein similarity for the influenza season of 99.1% ± 0.08% compared with the 2018–2019 influenza vaccine B/Yamagata component, B/Phuket/3073/2013-like virus (clade Y3), which was included in the quadrivalent vaccine only (data not shown).

Vaccine effectiveness

For the VE analysis, data were limited to surveillance weeks 46–12 (10 Nov. 2019 to 21 March 2020). There were 2,299 influenza-positive cases and 3,518 influenza-negative controls included in the VE analysis (Table 2). Of the influenza-positive cases, 46.1% had been vaccinated against influenza and 61.3% of the influenza-negative controls had been vaccinated. Influenza A and influenza B accounted for 53.4% and 46.6% of influenza-positive cases, respectively. Of the 1,227 outpatients infected with influenza A virus, only a small proportion (7.3%) were infected with influenza A(H3N2) virus (Table 2).

Among medically attended beneficiaries, adjusted VE against laboratory-confirmed influenza types was 46% (95% CI: 40%–52%) overall, including 38% (95% CI: 29%–47%) against influenza A(H1N1)pdm09, 55% (95% CI: 30%–71%) against influenza A(H3N2), and 51% (95% CI: 43%–58%) against influenza B (Figure 3). In addition, VE was estimated against any influenza viruses by age group. For children, the adjusted VE was 45% (95% CI: 36%–53%) against all influenza viruses, including 32% (95% CI: 16%–45%) against influenza A(H1N1)pdm09, 69% (95% CI: 43%–83%) against influenza A(H3N2), and 49% (95% CI: 38%–57%) against influenza B. In contrast, the adjusted VE for adults (18–64 years of age) was 46% (95% CI: 36%–55%) against any influenza viruses, including 43% (95% CI: 30%–53%) against influenza A(H1N1)pdm09, 33% (95% CI:-29%–65%) against influenza A(H3N2), and 53% (37%–64%) against influenza B. For elderly adults (≥65 years of age), none of the estimates of VE against any influenza viruses were statistically significant (Figure 3).

Editorial Comment

During the 2018–2019 influenza season, influenza B activity was low; however, for the 2019–2020 influenza season, influenza B made an early appearance and predominated at the start of the season, then maintained high activity until the end of March 2020. Influenza A(H1N1)pdm09 was active during the 2018–2019 influenza season, but its activity was higher during the 2019–2020 influenza season. In contrast to relatively high influenza A(H1N1)pdm09 activity during the 2019–2020 influenza seasons, influenza A(H3N2) was the dominant influenza A subtype circulating during the 2018–2019 season, but its activity was very low during the 2019–2020 influenza season. Overall, the magnitude of the influenza positivity rate during the 2019–2020 influenza season was similar to that during the 2018–2019 influenza season, with a peak influenza positivity among ILI-related specimens of 44%.

During the 2019–2020 influenza season, multiple genetic clades circulated for influenza A(H1N1)pdm09, A(H3N2), and B/Victoria. For these 3 (sub)types, the predominantly circulating genetic clades differed from the strain composition of the 2019–2020 influenza vaccine, with data suggesting that these clades are antigenically distinct with reduced inhibition by the vaccine.6 Influenza viruses from these predominating clades were selected for the 2020–2021 influenza vaccine recommendations,6 and there are no indications in the current data to suggest significant genetic changes in the circulating strains from the vaccine selections.

For the 2018–2019 influenza season, DODGRS reported that adjusted VE against any influenza in the DOD beneficiary population was lower (30%; 95% CI: 22%–38%) than for the 2019–2020 influenza season.1 Similarly, a lower VE (29%; 95% CI: 21%–35%) was found among participants during the 2018–2019 season using U.S. Influenza Vaccine Effectiveness Network data.7 The decreased VE was associated with the spread of antigenically drifted influenza A(H3N2) viruses during the 2018–2019 season.7 However, for the 2019–2020 influenza season, the estimated VE against all influenza based on DOD beneficiaries regardless of age group was higher (46%; 95% CI: 40%–52%) than the VE for the previous season. This finding is consistent with the interim VE estimate (45%; 95% CI: 36%–53%) against any influenza virus obtained using data from 4,112 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network during 23 Oct. 2019–25 Jan. 2020.8 The end-of-season VE estimates from the current analysis suggested that the 2019–2020 season's influenza vaccine was moderately effective against influenza viruses.

VE estimates were adjusted using potential confounders (e.g., age group, specimen collection date, geographical region) as covariates in multiple logistic regression models. However, due to the lack of randomization, inherent in any observational study, it is difficult to rule out unmeasured confounding factors (e.g., vaccination history) as a possible alternative explanation for the findings. In addition, the efforts to estimate the effect of vaccination rely on the DOD surveillance platform for data acquisition. The findings in the current study might be subject to limitations during the DOD surveillance data collection process. One important limitation is potential non-differential misclassification of vaccination status due to poor recall or record errors on the self-reported questionnaire.9 Furthermore, it should be noted that VE was estimated from data across geographically disparate areas. Although effort was made to statistically adjust for the potential confounding effect of geographical region, there may still be residual heterogeneity across geographical regions that was not accounted for, which would potentially impact the estimation of VE.

The overall outpatient population was relatively large for estimating VE. However, when outpatients were stratified based on age group and influenza virus sub(type) or lineage, VE in certain subgroups of interest could not be accurately estimated or even at all. For instance, in the current study, it was not possible to estimate VE against influenza A(H3N2) in the elderly. To improve the statistical power of tests, further study is warranted to accurately estimate VE, by combining DODGRS surveillance data over multiple influenza seasons using generalized linear mixed modeling. Indeed, the measurement of influenza VE can be affected by many factors such as age and health of influenza vaccine recipients, (sub) type/lineage of circulating viruses, as well as the study methodology used.10 Combining data from multiple influenza seasons may permit influenza VE analysis of relationships between VE and several viral and host factors.

Author Affiliations: Author affiliations: Defense Health Agency/Armed Forces Health Surveillance Division-Air Force Satellite–U.S. Air Force School of Aerospace Medicine, Wright-Patterson Air Force Base, OH (Dr. Hu, Mr. Kwaah, Ms. DeMarcus, Mr. Thervil, Dr. Sjoberg, Lt Col Robbins); JYG Innovations, LLC, Dayton, OH (Dr. Hu, Mr. Kwaah, Mr. Gruner, Ms. DeMarcus, Mr. Thervil, Dr. Sjoberg); U.S. Air Force School of Aerospace Medicine epidemiology laboratory, Wright-Patterson Air Force Base, OH (Mr. Gruner, Dr. Fries).

Acknowledgements: The authors would like to thank the Department of Defense Global Respiratory Pathogen Surveillance Program and its sentinel partners, and the U.S. Air Force School of Aerospace Medicine epidemiology laboratory for their valuable contributions to this work.

References

  1. Kersellius GD, Gruner WE, Fries AC, DeMarcus LS, Robbins AS. Respiratory pathogen surveillance trends and influenza vaccine effectiveness estimates for the 2018-2019 season among Department of Defense beneficiaries. MSMR. 2020;27(1):17–23.
  2. DeMarcus L, Shoubaki L, Federinko S. Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017–2018 influenza season. Vaccine. 2019;37:4015–4021.
  3. Shepard SS, Meno S, Bahl J, Wilson MM, Barnes J, Neuhaus E. Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genomics. 2016;17:708.
  4. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999;41:95–98.
  5. DNASTAR: Lasergene Core Suite (RRID:SCR_000291).
  6. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. Accessed 29 December 2020. https://www. who.int/influenza/vaccines/virus/recommendations/ 202002_recommendation.pdf
  7. Flannery B, Garten Kondor RJ, Chung JR, et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018v2019 season. J Infect Dis. 2020;221:8–15.
  8. Dawood FS, Chung JR, Kim SS, et al. Interim estimates of 2019-20 seasonal influenza vaccine effectiveness–United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:177–182.
  9. Lynch LC, Coleman R, DeMarcus L, et al. Department of Defense midseason estimates of vaccine effectiveness for the 2018-2019 influenza season. MSMR. 2019;26(7):24–27.
  10. Centers for Disease Control and Prevention. How flu vaccine effectiveness and efficacy is measured: questions and answers. Accessed 29 December 2020. https://www.cdc.gov/flu/vaccineswork/ effectivenessqa.htm

FIGURE 1a. Number of influenza-positive specimens, by influenza (sub)type and surveillance week, DoD beneficiaries, 2018–2019 and 2019–2020 influenza seasons

FIGURE 1b. Percentage of influenza-positive specimens, by influenza (sub)type and surveillance week, DoD beneficiaries, 2018–2019 and 2019–2020 influenza seasons

FIGURE 2a. Influenza A(H1N1)pdm09 clade dynamics, DoD beneficiaries, 2019–2020 influenzaseason (n=1,157)

FIGURE 2b. Influenza A(H3N2) clade dynamics, DoD beneficiaries, 2019–2020 influenza season (n=255)

FIGURE 2c . Influenza B/Victoria clade dynamics, DoD beneficiaries, 2019–2020 influenza season (n=1,229)

FIGURE 3. Adjusted end-of-season vaccine effectiveness estimates, by influenza (sub)type, and age group, DoD beneficiaries, 2019–2020 influenza season

TABLE 1. Influenza and other respiratory pathogens, DoD beneficiaries, 2019–2020 influenza season

TABLE 2. Characteristics of the surveillance population used for vaccine effectiveness analysis, DoD beneficiaries, 2019–2020 influenza season

You also may be interested in...

Re-evaluation of the MSMR Case Definition for Incident Cases of Malaria

Article
2/1/2019
Anopheles merus

The MSMR has been publishing the results of surveillance studies of malaria since 1995. The standard MSMR case definition uses Medical Event Reports and records of hospitalizations in counting cases of malaria. This report summarizes the performance of the standard MSMR case definition in estimating incident cases of malaria from 2015 through 2017. Also explored was the potential surveillance value of including outpatient encounters with diagnoses of malaria or positive laboratory tests for malaria in the case definition. The study corroborated the relative accuracy of the MSMR case definition in estimating malaria incidence and provided the basis for updating the case definition in 2019 to include positive laboratory tests for malaria antigen within 30 days of an outpatient diagnosis.

Recommended Content:

Medical Surveillance Monthly Report

Update: Malaria, U.S. Armed Forces, 2018

Article
2/1/2019
Anopheles merus

Malaria infection remains an important health threat to U.S. service mem­bers who are located in endemic areas because of long-term duty assign­ments, participation in shorter-term contingency operations, or personal travel. In 2018, a total of 58 service members were diagnosed with or reported to have malaria. This represents a 65.7% increase from the 35 cases identi­fied in 2017. The relatively low numbers of cases during 2012–2018 mainly reflect decreases in cases acquired in Afghanistan, a reduction due largely to the progressive withdrawal of U.S. forces from that country. The percentage of cases of malaria caused by unspecified agents (63.8%; n=37) in 2018 was the highest during any given year of the surveillance period. The percent­age of cases identified as having been caused by Plasmodium vivax (10.3%; n=6) in 2018 was the lowest observed during the 10-year surveillance period. The percentage of malaria cases attributed to P. falciparum (25.9 %) in 2018 was similar to that observed in 2017 (25.7%), although the number of cases increased. Malaria was diagnosed at or reported from 31 different medical facilities in the U.S., Afghanistan, Italy, Germany, Djibouti, and Korea. Pro­viders of medical care to military members should be knowledgeable of and vigilant for clinical manifestations of malaria outside of endemic areas.

Recommended Content:

Medical Surveillance Monthly Report

Thyroid Disorders, Active Component, U.S. Armed Forces, 2008–2017

Article
12/1/2018
A U.S. naval officer listens through his stethoscope to hear his patient’s lungs at Camp Schwab in Okinawa, Japan in 2018. (Photo courtesy of U.S. Marine Corps) photo by Lance Cpl. Cameron Parks)

This analysis describes the incidence and prevalence of five thyroid disorders (goiter, thyrotoxicosis, primary/not otherwise specified [NOS] hypothyroidism, thyroiditis, and other disorders of the thyroid) among active component service members between 2008 and 2017. During the 10-year surveillance period, the most common incident thyroid disorder among male and female service members was primary/NOS hypothyroidism and the least common were thyroiditis and other disorders of thyroid. Primary/NOS hypothyroidism was diagnosed among 8,641 females (incidence rate: 43.7 per 10,000 person-years [p-yrs]) and 11,656 males (incidence rate: 10.2 per 10,000 p-yrs). Overall incidence rates of all thyroid disorders were 3 to 5 times higher among females compared to males. Among both males and females, incidence of primary/NOS hypothyroidism was higher among non-Hispanic white service members compared with service members in other race/ethnicity groups. The incidence of most thyroid disorders remained stable or decreased during the surveillance period. Overall, the prevalence of most thyroid disorders increased during the first part of the surveillance period and then either decreased or leveled off.31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Incidence and Prevalence of the Metabolic Syndrome Using ICD-9 and ICD-10 Diagnostic Codes, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

This report uses ICD-9 and ICD-10 codes (277.7 and E88.81, respectively) for the metabolic syndrome (MetS) to summarize trends in the incidence and prevalence of this condition among active component members of the U.S. Armed Forces between 2002 and 2017. During this period, the crude overall incidence rate of MetS was 7.5 cases per 100,000 person-years (p-yrs). Compared to their respective counterparts, overall incidence rates were highest among Asian/Pacific Islanders, Air Force members, and warrant officers and were lowest among those of other/unknown race/ethnicity, Marine Corps members, and junior enlisted personnel and officers. During 2002–2017, the annual incidence rates of MetS peaked in 2009 at 11.6 cases per 100,000 p-yrs and decreased to 5.9 cases per 100,000 p-yrs in 2017. Annual prevalence rates of MetS increased steadily during the first 11 years of the surveillance period reaching a high of 38.9 per 100,000 active component service members in 2012, after which rates declined slightly to 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

Adrenal Gland Disorders, Active Component, U.S. Armed Forces, 2002–2017

Article
12/1/2018

During 2002–2017, the most common incident adrenal gland disorder among male and female service members was adrenal insufficiency and the least common was adrenomedullary hyperfunction. Adrenal insufficiency was diagnosed among 267 females (crude overall incidence rate: 8.2 cases per 100,000 person-years [p-yrs]) and 729 males (3.9 per 100,000 p-yrs). In both sexes, overall rates of other disorders of adrenal gland and Cushing’s syndrome were lower than for adrenal insufficiency but higher than for hyperaldosteronism, adrenogenital disorders, and adrenomedullary hyperfunction. Crude overall rates of adrenal gland disorders among females tended to be higher than those of males, with female:male rate ratios ranging from 2.1 for adrenal insufficiency to 5.5 for androgenital disorders and Cushing’s syndrome. The highest overall rates of adrenal insufficiency for males and females were among non-Hispanic white service members. Among females, rates of Cushing's syndrome and other disorders of adrenal gland were 31.6 per 100,000 active component service members in 2017. Validation of ICD-9/ICD-10 diagnostic codes for MetS using the National Cholesterol Education Program Adult Treatment Panel III criteria is needed to establish the level of agreement between the two methods for identifying this condition.

Recommended Content:

Medical Surveillance Monthly Report

2018 #ColdReadiness Twitter chat recap: Preventing cold weather injuries for service members and their families

Fact Sheet
2/5/2018

To help protect U.S. armed forces, the Armed Forces Health Surveillance Branch (AFHSB) hosted a live #ColdReadiness Twitter chat on Wednesday, January 24th, 12-1:30 pm EST to discuss what service members and their families need to know about winter safety and preventing cold weather injuries as the temperatures drop. This fact sheet documents highlights from the Twitter chat.

Recommended Content:

Medical Surveillance Monthly Report | Winter Safety | Medical and Dental Preventive Care Fitness | Health Readiness & Combat Support

Demographic and Military Traits of Service Members Diagnosed as Traumatic Brain Injury Cases

Fact Sheet
3/30/2017

This fact sheet provides details on the demographic and military traits of service members diagnosed as traumatic brain injury (TBI) cases during a 16-year surveillance period from 2001 through 2016, a total of 276,858 active component service members received first-time diagnoses of TBI - a structural alteration of the brain or physiological disruption of brain function caused by an external force.

Recommended Content:

Armed Forces Health Surveillance Division | Medical Surveillance Monthly Report

Heat Illnesses by Location, Active Component, U.S. Armed Forces, 2012-2016 Fact Sheet

Fact Sheet
3/30/2017

This fact sheet provides details on heat illnesses by location during a five-year surveillance period from 2012 through 2016. 11,967 heat-related illnesses were diagnosed at more than 250 military installations and geographic locations worldwide. Three Army Installations accounted for close to one-third of all heat illnesses during the period.

Recommended Content:

Armed Forces Health Surveillance Division | Medical Surveillance Monthly Report

Rhabdomyolysis by Location, Active Component, U.S. Armed Forces, 2012-2016 Fact Sheet

Fact Sheet
3/30/2017

This fact sheet provides details on Rhabdomyolysis by location for active component, U.S. Armed Forces during a five-year surveillance period from 2012 through 2016. The medical treatment facilities at nine installations diagnosed at least 50 cases each and, together approximately half (49.9%) of all diagnosed cases.

Recommended Content:

Armed Forces Health Surveillance Division | Medical Surveillance Monthly Report
<< < ... 11 12 13 > >> 
Showing results 181 - 189 Page 13 of 13
Refine your search
Last Updated: October 14, 2022
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery